Answers are grounded in this paper and cite their sources.
The value of Sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitor) therapy in individuals with heart failure with preserved EF (HFpEF) was unknown until the EMPEROR-Preserved trial. We aimed to assess the proportion of patients with HFpEF that are eligible for empagliflozin therapy within the Colombian Heart Failure Registry (RECOLFACA).
No takes yet. Share an insight, caveat, or question.
Gómez‐Mesa et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: